Aquestive Therapeutics (NASDAQ:AQST) CEO Sells $120,500.00 in Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) CEO Daniel Barber sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $4.82, for a total transaction of $120,500.00. Following the transaction, the chief executive officer owned 652,317 shares in the company, valued at $3,144,167.94. The trade was a 3.69% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aquestive Therapeutics Trading Down 0.8%

Shares of NASDAQ AQST traded down $0.04 during midday trading on Wednesday, reaching $4.77. The company had a trading volume of 865,352 shares, compared to its average volume of 3,056,346. Aquestive Therapeutics, Inc. has a 1 year low of $2.93 and a 1 year high of $7.55. The business’s 50-day simple moving average is $4.41 and its 200 day simple moving average is $4.27. The stock has a market cap of $598.81 million, a P/E ratio of -7.35 and a beta of 1.48.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.08). The firm had revenue of $13.82 million for the quarter, compared to analysts’ expectations of $11.42 million. Analysts predict that Aquestive Therapeutics, Inc. will post -0.5 earnings per share for the current year.

Wall Street Analysts Forecast Growth

AQST has been the subject of several research analyst reports. Wall Street Zen upgraded Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Friday, July 17th. Cantor Fitzgerald restated an “overweight” rating and set a $11.00 price objective on shares of Aquestive Therapeutics in a research note on Thursday, September 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $9.17.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Sugar Maple Asset Management LLC lifted its stake in Aquestive Therapeutics by 5.9% in the 1st quarter. Sugar Maple Asset Management LLC now owns 58,060 shares of the company’s stock valued at $241,000 after buying an additional 3,210 shares in the last quarter. International Assets Investment Management LLC increased its stake in Aquestive Therapeutics by 27.0% during the 1st quarter. International Assets Investment Management LLC now owns 22,895 shares of the company’s stock worth $95,000 after buying an additional 4,870 shares in the last quarter. ProShare Advisors LLC raised its holdings in shares of Aquestive Therapeutics by 28.7% during the fourth quarter. ProShare Advisors LLC now owns 24,482 shares of the company’s stock valued at $158,000 after acquiring an additional 5,461 shares during the last quarter. Quantinno Capital Management LP raised its holdings in shares of Aquestive Therapeutics by 52.8% during the first quarter. Quantinno Capital Management LP now owns 18,014 shares of the company’s stock valued at $75,000 after acquiring an additional 6,221 shares during the last quarter. Finally, Engineers Gate Manager LP lifted its position in shares of Aquestive Therapeutics by 20.5% in the second quarter. Engineers Gate Manager LP now owns 49,879 shares of the company’s stock valued at $207,000 after acquiring an additional 8,496 shares in the last quarter. 32.45% of the stock is owned by institutional investors and hedge funds.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines delivered through its PharmFilm technology. The company’s dissolvable oral-film platform is designed to provide alternatives to conventional tablets, capsules and injectable therapies, with potential benefits for patients who have difficulty swallowing or require rapid, convenient administration.

Aquestive’s commercial products include Exservan, an oral film formulation of riluzole for people with amyotrophic lateral sclerosis; Libervant, a buccal film formulation of diazepam for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity; and Sympazan, an oral film formulation of clonazepam for the treatment of seizures associated with Lennox-Gastaut syndrome.